Headquarters, R&D and manufacturing in Southport, North Carolina, USA.
Ken Hoffman, Founder
Ken Hoffman founded Cygnus Technologies in 1997 to provide analytical solutions to the rapidly growing biopharmaceutical industry and is a thought leader in the field of biotherapeutic impurity analysis. Prior to starting Cygnus, Ken worked in the clinical diagnostics field for a number of companies, including bioMerieux, developing automated systems and extensive menus of assays for infectious disease, metabolic disease, drugs and hormones. Ken holds multiple degrees, including a M.S. in Radiation Biology/Immunology from University of Iowa and a Certificate in Biomedical Research Management from the Harvard School of Public Health.
Christine Dolan, Chief Operating Officer
Christine was appointed COO for Cygnus Technologies in October 2017. She is accountable for all operations including designing / implementing business processes and organizational structures / strategies to ensure continued longevity and growth. Prior to joining Cygnus Technologies, she was the SVP of Product Development at Catalent Pharma Solutions and served in several senior global Quality, Operations and Business Unit leadership roles during her 8 year tenure. In addition, she has held progressive operational management roles at GE Healthcare and Amersham Health. Christine started her career as a Microbiologist, and holds a B.S. in Biology from Lenoir Rhyne College.
Eric Bishop, Vice President of Research and Development
Eric oversees the research and development team at Cygnus Technologies and is responsible for new product development and technical support. Eric joined Cygnus Technologies in 2010, bringing a background in R&D for several biopharmaceutical companies. He holds multiple degrees, including an MBA from Hood College, an M.S. in biotechnology from Johns Hopkins University and a B.S. from Radford University.
David Weber, Vice President and Chief Commercial Officer
David comes to Maravai LifeSciences with over 35 years of experience in life sciences industry commercial leadership and general management. David is responsible for all marketing, sales, product development, commercial strategy, service, and support for all Maravai LifeSciences portfolio companies. Prior to joining Maravai LifeSciences, David served as Executive Vice President and Chief Commercial Officer for Affymetrix leading up to its acquisition by Thermo Fisher Scientific. Earlier in his career, David held a variety of commercial leadership roles in life science companies including Amersham Biosciences (GE Healthcare), Eksigent Technologies, Cyntellect, Stratagene, and The Linus Group.
Harjit Kullar, Vice President of Marketing
Harjit comes to Maravai LifeSciences with over 15 years of experience in sales and marketing in the life sciences and diagnostics industries, most recently holding the position of Vice President of Marketing at Transgenomic. Earlier in his career, Harjit held a variety of commercial leadership roles in life science companies including Bio-Rad Laboratories, Thermo Fisher Scientific, Life Technologies, LifeSpan BioSciences and Abcam. Harjit received a BSc in Biochemistry & Pharmacology from University of Southampton, a Ph.D. in Cancer Biology from University of Birmingham and an MBA from University of Cambridge.